Search results for "Bone Neoplasm"

showing 10 items of 148 documents

Minimally invasive procedures for the management of vertebral bone pain due to cancer: The EAPC recommendations.

2015

Image-guided percutaneous ablation methods have proved effective for treatment of benign bone tumors and for palliation of metastases involving the bone. However, the role of these techniques is controversial and has to be better defined in the setting of palliative care.A systematic review of the existing data regarding minimally invasive techniques for the pain management of vertebral bone metastases was performed by experts of the European Palliative Care Research Network.Only five papers were taken into consideration after performing rigorous screening according to inclusion and exclusion criteria (low number of patients, retrospective series, proceedings).According to the present data …

medicine.medical_specialtyPalliative carePercutaneousmedicine.medical_treatmentMEDLINEBone NeoplasmsCryosurgeryCryosurgerylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawmedicineBack painHumansMinimally Invasive Surgical ProceduresRadiology Nuclear Medicine and imaging030212 general & internal medicinebusiness.industryHematologyGeneral MedicineSpineOncologyBack Pain030220 oncology & carcinogenesisMeta-analysisInclusion and exclusion criteriaRadiologymedicine.symptombusinessActa oncologica (Stockholm, Sweden)
researchProduct

Spinal metastases: Is stereotactic body radiation therapy supported by evidences?

2016

Stereotactic body radiotherapy (SBRT) is becoming widely adopted in the treatment of primary and secondary tumors. Spinal bone metastases are frequently discovered in cancer patients, and in the past have been usually treated with a palliative goal. Nevertheless, in some particular clinical settings, such as oligometastatic patients and/or those with a long life expectancy, spinal SBRT could be considered a valid therapeutic option to obtain long-lasting palliation and, when possible, with a curative goal. This review aims to summarize available clinical and dosimetric data of published studies about spinal SBRT.

medicine.medical_specialtyPalliative careStereotactic body radiation therapymedicine.medical_treatment2720 HematologyBone Neoplasms610 Medicine & healthClinical settingsRadiosurgeryRadiosurgery030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineDosimetryFractures CompressionPalliative radiotherapymedicineHumansSBRTSpinal NeoplasmsToxicitySpine metastasesbusiness.industryPalliative CareCompressionCancerRadiotherapy DosageHematologymedicine.disease10044 Clinic for Radiation OncologySurgeryTreatment OutcomeOncologyLocal controlDosimetry; Local control; Palliative radiotherapy; SBRT; Spine metastases; Toxicity; Bone Neoplasms; Evidence-Based Practice; Fractures Compression; Humans; Palliative Care; Radiotherapy Dosage; Spinal Fractures; Spinal Neoplasms; Treatment Outcome; Radiosurgery; Hematology; Oncology; Geriatrics and GerontologyEvidence-Based Practice030220 oncology & carcinogenesisSpinal Fractures2730 OncologySecondary tumorsGeriatrics and GerontologySpinal metastasesbusinessFracturesStereotactic body radiotherapyCritical Reviews in Oncology/Hematology
researchProduct

Establishment and Characterization of a Continuous Human Chondrosarcoma Cell Line, ch-2879: Comparative Histologic and Genetic Studies with Its Tumor…

2003

Chondrosarcomas are malignant cartilage-forming tumors that represent the second most common malignant solid tumor of bone. These biologically poorly understood neoplasms vary considerably in clinical presentation and biologic behavior. Chemotherapy and radiation therapy are generally ineffective. Here we describe the establishment and characterization of a new human chondrosarcoma cell line named ch-2879, and we compare the cell line with its tumor of origin. The cell line was established from a recurrent grade 3 chondrosarcoma of the chest wall and characterized by growth kinetics and morphologic studies. Immunocytochemistry and RT-PCR were performed to examine the expression of cartilage…

medicine.medical_specialtyPathologyPopulationCell Culture TechniquesChondrosarcomaBone NeoplasmsChromosomal translocationVimentinPathology and Forensic MedicineCyclin D1Tumor Cells CulturedmedicineHumanseducationMolecular BiologyMetaphaseChromosome Aberrationseducation.field_of_studymedicine.diagnostic_testbiologyCytogeneticsKaryotypeCell BiologyFlow Cytometrymedicine.diseaseMicroscopy ElectronKaryotypingbiology.proteinCancer researchChondrosarcomaFluorescence in situ hybridizationLaboratory Investigation
researchProduct

Incidence Patterns and Trends of non-Central Nervous System Solid Tumours in Children and Adolescents. A Collaborative Study of the Spanish Populatio…

2016

Journal Article; OBJECTIVE To describe incidence patterns and trends in children (0-14 years) and adolescents (15-19 age-range) with solid tumours, except those of central nervous system (CNS), in Spain. METHODS Cases were drawn from eleven Spanish population-based cancer registries. Incidence was estimated for the period 1983-2007 and trends were evaluated using Joinpoint regression analysis. RESULTS The studied tumour groups accounted for 36% of total childhood cancers and 47.6% of those diagnosed in adolescence with annual rates per million of 53.5 and 89.3 respectively. In children 0 to 14 years of age, Neuroblastoma (NB) was the commonest (7.8%) followed by Soft-tissue sarcomas (STS) (…

medicine.medical_specialtyPediatricsJoinpoint regression:Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms Neuroepithelial::Neuroectodermal Tumors Primitive::Neuroectodermal Tumors Primitive Peripheral::Neuroblastoma [Medical Subject Headings]Central nervous systemEspaña03 medical and health sciences0302 clinical medicine030225 pediatricsInternal medicineNeuroblastoma:Health Care::Population Characteristics::Demography::Vital Statistics::Morbidity::Incidence [Medical Subject Headings]medicineCarcinoma:Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms Glandular and Epithelial::Carcinoma [Medical Subject Headings]canceradolescentsAdolescente:Named Groups::Persons::Age Groups::Child [Medical Subject Headings]childhood:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]business.industryIncidence (epidemiology)Cancermedicine.diseaseNeoplasiasSpanish populationmedicine.anatomical_structureOncologyEl Niñopopulation-based studySpain030220 oncology & carcinogenesisNiño:Named Groups::Persons::Age Groups::Adolescent [Medical Subject Headings]solid tumourincidence:Diseases::Neoplasms::Neoplasms by Site::Bone Neoplasms [Medical Subject Headings]businessIncidenciaResearch PaperSpain.
researchProduct

Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.

2011

Receptor activator of NFκB ligand (RANKL), RANK, and osteoprotegerin (OPG) represent the key regulators of bone metabolism both in normal and pathological conditions, including bone metastases. To our knowledge, no previous studies investigated and compared RANK expression in primary tumors and in bone metastases from the same patient. We retrospectively examined RANK expression by immunohistochemistry in 74 bone metastases tissues from solid tumors, mostly breast, colorectal, renal, lung, and prostate cancer. For 40 cases, tissue from the corresponding primary tumor was also analyzed. Sixty-six (89%) of the 74 bone metastases were RANK-positive and, among these, 40 (59.5%) showed more than…

medicine.medical_specialtySettore MED/06 - Oncologia MedicaPhysiologyClinical Biochemistrycolorectal cancerBone NeoplasmsBone remodelingMetastasisProstate cancerbreast cancerOsteoprotegerinInternal medicinemedicineHumansbone metastasibiologyReceptor Activator of Nuclear Factor-kappa Bbusiness.industryMedicine (all)Bone metastasisCell Biologymedicine.diseasePrimary tumorbone metastasis; breast cancer; colorectal cancerImmunohistochemistryEndocrinologyBone Neoplasms; Humans; Immunohistochemistry; Receptor Activator of Nuclear Factor-kappa B; Medicine (all); Physiology; Clinical Biochemistry; Cell BiologyRANKLCancer researchbiology.proteinImmunohistochemistrybusinessJournal of cellular physiology
researchProduct

Multiple brown tumours of tertiary hyperparathyroidism in a renal transplant recipient: : a case report

2010

Tertiary Hyperparathyroidism (HPT) is an uncommon condition that affects patients with secondary HPT after a successful kidney transplant. Bone alterations are the main consequences of this endocrine condition, including the development of an osteolytic lesion called brown tumour. This paper reports an unusual case of multiple brown tumours located in the maxilla and mandible in a 58-year-old renal transplant recipient, with tertiary HPT. Incisional biopsies were performed and, in both samples, the histopathological diagnoses were giant cell lesions. Due to these diagnoses, the medical history of chronic renal failure, and high levels of serum calcium and PTH, lesions were diagnosed as mult…

medicine.medical_specialtyTotal parathyroidectomyBone NeoplasmsTertiary hyperparathyroidismOrgan transplantationNeoplasms Multiple PrimarymedicineEndocrine systemHumansMedical historyGeneral Dentistrybusiness.industryHyperparathyroidismMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Jaw NeoplasmsKidney TransplantationSurgeryOtorhinolaryngologyRenal transplantGiant cellMaxillaUNESCO::CIENCIAS MÉDICASSurgeryFemalebusiness
researchProduct

Condylar intramedullary intraosseous lipoma : contribution of a new case and review of the literature

2017

Background Lipoma is the most common benign tumour of the human body, being intraosseous involvement very rare. Just 1 to 4% of all cases of lipoma are located in the oral cavity, only 0.1% being intraosseous. The jaw is its most uncommon bone location. Etiology of intraosseous lipoma (IOL) is unknown, although several theories have been proposed. Usually asymptomatic, the symptoms, when present, will depend on its location and size. Its origin may be intraosseous or juxtacortical. A biopsy is essential for diagnosis, and definitive treatment involves resection or curettage of the lesion. The aim of this paper is to present a new case of intramedullary intraosseous lipoma of the mandible wi…

medicine.medical_specialtymedicine.medical_treatmentBenign Bone NeoplasmCase ReportLiposarcomaCondylelaw.inventionIntramedullary rod03 medical and health sciences0302 clinical medicinestomatognathic systemlawotorhinolaryngologic diseasesMedicineGeneral DentistryOral Medicine and Pathologybusiness.industryMandibleLipomamedicine.disease:CIENCIAS MÉDICAS [UNESCO]CurettageTemporomandibular jointSurgerybody regionsstomatognathic diseasesmedicine.anatomical_structure030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASbusiness030217 neurology & neurosurgery
researchProduct

Methotrexate-Loaded Polymethylmethacrylate Bone Cement for Local Bone Metastasis Therapy: Pilot Animal Study in the Rabbit Patellar Groove

2008

Local chemotherapy is an option in bone metastasis treatment. On the other hand, evaluation of side effects on bone is a difficult issue in drug development and biomaterials research. Most animal models to date are inappropriate or not feasible. Rabbits are an alternative to other bigger mammals and have an appropriate bone structure compared to rats and mice. The patellar groove model of the rabbit offers a standardized and sensitive model to evaluate bone-compromising drug effects. We tested the system with a reproducible polymethacrylate implant as carrier and loaded this system with methotrexate. Three methotrexate concentrations were used in the test samples (250 mg, 1 g and 4 g per 40…

medicine.medical_specialtymedicine.medical_treatmentBone NeoplasmsPilot ProjectsMetastasisDrug DiscoverymedicineAnimalsPolymethyl MethacrylatePharmacology (medical)PharmacologyChemotherapybusiness.industryBone CementsBone metastasisPatellaProstheses and ImplantsGeneral Medicinemedicine.diseaseBone cementSurgeryPre-clinical developmentDisease Models AnimalMethotrexateInfectious DiseasesOncologyPatellaMethotrexateRabbitsImplantbusinessmedicine.drugChemotherapy
researchProduct

Progestogens and risk of breast cancer: a link between bone and breast?

2015

This article reviews the data supporting the role of receptor activator of the nuclear factor kappa (RANK) and its ligand, RANKL, in progestogen-induced breast cancer. Both experimental and clinical studies have been included. The expression of both RANK and RANKL has been described in epithelial cells of both mice and humans. Experiments of gain and loss of function in mice have shown that RANK/RANKL mediate alveologenesis during pregnancy or the estrous cycle. Moreover, the participation of the RANK/RANKL has been detected in models of breast carcinogenesis associated with progestogens-like medroxyprogesterone acetate. Recent clinical studies have found that the expression of RANK is asso…

musculoskeletal diseases0301 basic medicineEndocrinology Diabetes and MetabolismOsteoclastsBone NeoplasmsBreast NeoplasmsMice03 medical and health sciences0302 clinical medicineEndocrinologyBreast cancerRisk FactorsmedicineAnimalsHumansMedroxyprogesterone acetateBreastReceptorProgesteroneLoss functionEstrous cyclePregnancyReceptor Activator of Nuclear Factor-kappa BbiologyActivator (genetics)business.industryRANK LigandObstetrics and Gynecologymedicine.disease030104 developmental biologyRANKL030220 oncology & carcinogenesisImmunologybiology.proteinCancer researchFemaleProgestinsbusinessmedicine.drugGynecological Endocrinology
researchProduct

The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing s…

2016

SATB2 is commonly expressed in osteosarcomas. Although apparently being a valuable diagnostic marker for differentiating between small cell osteosarcoma (SCO) and other small round cell tumors of bone, for instance Ewing sarcoma family of tumors (ESFT), it has not been tested in a large series of ESFT and chondrosarcomas so far. We studied the immunohistochemical expression of SATB2 in 42 osteosarcomas, 31 chondrosarcomas, and 371 genetically confirmed ESFT. SATB2 positivity was detected in 90.4% of osteosarcomas, 87.5% of SCO, 91.3% of osteoblastic osteosarcomas, and in all chondroblastic and parosteal osteosarcomas. The osteoblastic and SCO subtypes expressed SATB2 more intensely than oth…

musculoskeletal diseases0301 basic medicinePathologymedicine.medical_specialtyCD99ChondrosarcomaBone NeoplasmsSarcoma EwingSensitivity and SpecificitySmall Cell OsteosarcomaPathology and Forensic MedicineDiagnosis Differential03 medical and health sciences0302 clinical medicineChondroblastic OsteosarcomaBiomarkers TumormedicineHumansRetrospective StudiesOsteosarcomabusiness.industryOsteoidMatrix Attachment Region Binding ProteinsCell Biologymusculoskeletal systemmedicine.diseaseImmunohistochemistry030104 developmental biology030220 oncology & carcinogenesisImmunohistochemistryOsteosarcomaSarcomaChondrosarcomabusinessTranscription FactorsPathology - Research and Practice
researchProduct